Allspring Global Investments Holdings LLC Grows Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

Allspring Global Investments Holdings LLC increased its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 54.0% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 23,775 shares of the biopharmaceutical company's stock after acquiring an additional 8,338 shares during the quarter. Allspring Global Investments Holdings LLC's holdings in TG Therapeutics were worth $898,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Vanguard Group Inc. boosted its position in shares of TG Therapeutics by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 15,596,480 shares of the biopharmaceutical company's stock valued at $469,454,000 after acquiring an additional 209,190 shares during the last quarter. Soleus Capital Management L.P. raised its holdings in TG Therapeutics by 5.8% during the 4th quarter. Soleus Capital Management L.P. now owns 2,681,242 shares of the biopharmaceutical company's stock valued at $80,705,000 after buying an additional 146,702 shares during the period. Clearbridge Investments LLC purchased a new stake in TG Therapeutics during the 4th quarter valued at $55,237,000. Northern Trust Corp raised its holdings in TG Therapeutics by 8.6% during the 4th quarter. Northern Trust Corp now owns 1,532,929 shares of the biopharmaceutical company's stock valued at $46,141,000 after buying an additional 120,785 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its holdings in TG Therapeutics by 7.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,269,513 shares of the biopharmaceutical company's stock valued at $38,212,000 after buying an additional 84,904 shares during the period. Institutional investors own 58.58% of the company's stock.

TG Therapeutics Trading Up 6.5%

NASDAQ:TGTX traded up $2.31 during midday trading on Wednesday, hitting $37.92. 1,860,721 shares of the company traded hands, compared to its average volume of 2,897,422. The firm's fifty day moving average is $36.49 and its 200-day moving average is $35.19. TG Therapeutics, Inc. has a 12-month low of $16.65 and a 12-month high of $46.48. The firm has a market capitalization of $6.02 billion, a P/E ratio of 158.00 and a beta of 1.91. The company has a current ratio of 4.02, a quick ratio of 3.04 and a debt-to-equity ratio of 1.03.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.16). TG Therapeutics had a net margin of 10.13% and a return on equity of 18.88%. The company had revenue of $120.86 million for the quarter, compared to analysts' expectations of $117.07 million. During the same quarter in the previous year, the company posted ($0.07) EPS. The business's quarterly revenue was up 90.4% on a year-over-year basis. On average, sell-side analysts predict that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Insiders Place Their Bets

In related news, Director Yann Echelard sold 10,000 shares of the stock in a transaction on Friday, June 13th. The stock was sold at an average price of $36.94, for a total transaction of $369,400.00. Following the sale, the director owned 228,816 shares in the company, valued at approximately $8,452,463.04. This represents a 4.19% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 10.64% of the company's stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.